Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 2 (2005), Issue 2 (February)

1. Development, implementation, and evaluation of a community- and hospital-based respiratory syncytial virus prophylaxis program.
   Adv Neonatal Care, 5(1): 39-49. [Abstract] [Full-text]
2. Cellulose acetate butyrate microcapsules containing dextran ion-exchange resins as self-propelled drug release system.
   Biomaterials, 26(20): 4337-47. [Abstract] [Full-text]
3. Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens.
   Pacing Clin Electrophysiol, 28: S172-7. [Abstract] [Full-text]
4. Catheter-directed thrombolysis for the management of postpartum deep venous thrombosis.
   Acta Obstet Gynecol Scand, 84(2): 155-8. [Abstract] [Full-text]
5. Radical cystectomy in the elderly: Comparison of survival between younger and older patients.
   Cancer, 103(3): 546-52. [Abstract] [Full-text]
6. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
   Cancer, 103(3): 553-8. [Abstract] [Full-text]
7. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.
   Cancer, 103(3): 582-7. [Abstract] [Full-text]
8. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.
   Cancer, 103(3): 569-75. [Abstract] [Full-text]
9. Multicomponent therapeutics for networked systems.
   Nat Rev Drug Discov, 4(1): 71-8. [Abstract] [Full-text]
10. Oral versus intravenous rehydration of moderately dehydrated children: a randomized, controlled trial.
    Pediatrics, 115(2): 295-301. [Abstract] [Full-text]
11. Synthesis of mono-glucose-branched cyclodextrins with a high inclusion ability for doxorubicin and their efficient glycosylation using Mucor hiemalis endo-beta-N-acetylglucosaminidase.
    Bioorg Med Chem Lett, 15(4): 1009-13. [Abstract] [Full-text]
12. Inclusion complexes of N-sulfamoyloxazolidinones with beta-cyclodextrin.
    Bioorg Med Chem Lett, 15(4): 889-94. [Abstract] [Full-text]
13. A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors.
    J Neurooncol, 71(2): 181-7. [Abstract] [Full-text]
14. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
    J Neurooncol, 71(2): 161-8. [Abstract] [Full-text]
15. Patterns of specific antimigraine drug use--a study based on the records of 18 community pharmacies.
    Cephalalgia, 25(3): 214-8. [Abstract] [Full-text]
16. Hormone replacement therapy in women with spinal cord injury - a survey with literature review.
    Spinal Cord, 43(2): 67-73. [Abstract] [Full-text]
17. Prospective clinical trials of biotherapies in solid tumors: a 5-year survey.
    Cancer Immunol Immunother, 54(1): 44-50. [Abstract] [Full-text]
18. Preparation, premedication, and surveillance.
    Endoscopy, 37(2): 101-9. [Abstract] [Full-text]
19. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory.
    Breast Cancer Res Treat, 89(2): 187-97. [Abstract] [Full-text]
20. Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors.
    An Acad Bras Cienc, 77(1): 113-24. [Abstract] [Full-text]
21. ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.
    Hematol J, 5(7): 553-8. [Abstract] [Full-text]
22. Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa.
    J Am Acad Dermatol, 52(2): 20-3. [Abstract] [Full-text]
23. Gender differences in drug use and expenditures in a privately insured population of older adults.
    J Womens Health (Larchmt), 14(1): 73-81. [Abstract] [Full-text]
24. The age/gender interface in geriatric pharmacotherapy.
    J Womens Health (Larchmt), 14(1): 68-72. [Abstract] [Full-text]
25. Reducing the risk of medication errors in women.
    J Womens Health (Larchmt), 14(1): 61-7. [Abstract] [Full-text]
26. Biological rhythms, medication safety, and women's health.
    J Womens Health (Larchmt), 14(1): 38-46. [Abstract] [Full-text]
27. Sex and racial differences in pharmacological response: effect of route of administration and drug delivery system on pharmacokinetics.
    J Womens Health (Larchmt), 14(1): 30-7. [Abstract] [Full-text]
28. Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab.
    Onkologie, 28(2): 95-7. [Abstract] [Full-text]
29. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
    Eur J Cancer, 41(3): 453-60. [Abstract] [Full-text]
30. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
    Eur J Cancer, 41(3): 398-403. [Abstract] [Full-text]
31. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.
    Ophthalmology, 112(2): 301-4. [Abstract] [Full-text]
32. Raf kinase inhibitors in oncology.
    Onkologie, 28(2): 101-7. [Abstract] [Full-text]
33. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.
    Onkologie, 28(2): 81-5. [Abstract] [Full-text]
34. Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone.
    Onkologie, 28(2): 73-8. [Abstract] [Full-text]
35. Influence of number needed to treat, costs and outcome on preferences for a preventive drug.
    Fam Pract, 22(1): 126-31. [Abstract] [Full-text]
36. Benefits of a prehospital stroke code system. Feasibility and efficacy in the first year of clinical practice in Barcelona, Spain.
    Cerebrovasc Dis, 19(2): 96-101. [Abstract] [Full-text]
37. Integrating cell-level kinetic modeling into the design of engineered protein therapeutics.
    Nat Biotechnol, 23(2): 191-4. [Abstract] [Full-text]
38. Long-term benefits of monteplase before coronary angioplasty in acute myocardial infarction.
    Am J Cardiol, 95(4): 506-8. [Abstract] [Full-text]
39. Bowen's disease of the nipple-a new method of treatment.
    Breast, 14(1): 65-7. [Abstract] [Full-text]
40. The effect of immediate breast reconstruction on adjuvant chemotherapy.
    Breast, 14(1): 18-21. [Abstract] [Full-text]
41. Elimination of major side effects due to ROS of therapeuticals through biotransformation control of the 57 cytochromes P450 isoenzymes.
    Med Hypotheses, 64(4): 802-5. [Abstract] [Full-text]
42. Interactions between melatonin and estrogen may regulate cerebrovascular function in women: clinical implications for the effective use of HRT during menopause and aging.
    Med Hypotheses, 64(4): 725-35. [Abstract] [Full-text]
43. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
    Nat Biotechnol, 23(2): 201-7. [Abstract] [Full-text]
44. Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport.
    J Pharm Sci, 94(3): 613-24. [Abstract] [Full-text]
45. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial.
    BMJ, 330(7486): 293. [Abstract] [Full-text]
46. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
    Z Gastroenterol, 43(2): 155-61. [Abstract] [Full-text]
47. Managing drugs safely.
    Semin Fetal Neonatal Med, 10(1): 73-81. [Abstract] [Full-text]
48. Assessment and treatment of perfusion abnormalities in the emergency patient.
    Vet Clin North Am Small Anim Pract, 35(2): 319-42. [Abstract] [Full-text]
49. Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
    Eur J Surg Oncol, 31(2): 147-52. [Abstract] [Full-text]
50. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
    J Cancer Res Clin Oncol, 131(4): 255-60. [Abstract] [Full-text]
51. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation.
    J Cancer Res Clin Oncol, 131(4): 214-8. [Abstract] [Full-text]
52. Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial.
    J Clin Endocrinol Metab, 90(2): 805-12. [Abstract] [Full-text]
53. The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer.
    Br J Cancer, 92(1): 47-54. [Abstract] [Full-text]
54. Effects of drugs on the fetus.
    Semin Fetal Neonatal Med, 10(2): 139-47. [Abstract] [Full-text]
55. The effect of processing on the structural characteristics of vancomycin-loaded amorphous calcium phosphate matrices.
    Biomaterials, 26(21): 4486-94. [Abstract] [Full-text]
56. In vitro study of anticancer drug doxorubicin in PLGA-based microparticles.
    Biomaterials, 26(21): 4476-85. [Abstract] [Full-text]
57. Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma.
    Neuro-oncol, 7(1): 41-8. [Abstract] [Full-text]
58. Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.
    Br J Cancer, 92(3): 475-9. [Abstract] [Full-text]
59. Non-small-cell lung cancer in a French department, (1982-1997): management and outcome.
    Br J Cancer, 92(3): 459-66. [Abstract] [Full-text]
60. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.
    Br J Cancer, 92(3): 467-74. [Abstract] [Full-text]
61. A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.
    Br J Cancer, 92(3): 445-8. [Abstract] [Full-text]
62. Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid.
    Br J Cancer, 92(2): 298-304. [Abstract] [Full-text]
63. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy.
    Br J Cancer, 92(2): 246-51. [Abstract] [Full-text]
64. Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
    Br J Cancer, 92(1): 24-9. [Abstract] [Full-text]
65. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.
    Br J Cancer, 92(1): 15-20. [Abstract] [Full-text]
66. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding.
    Br J Cancer, 92(1): 36-40. [Abstract] [Full-text]
67. Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13.
    Hum Gene Ther, 16(1): 57-67. [Abstract] [Full-text]
68. Assessing fluid responsiveness during open chest conditions.
    Br J Anaesth, 94(3): 318-23. [Abstract] [Full-text]
69. Time course of inhaled anaesthetic drug delivery using a new multifunctional closed-circuit anaesthesia ventilator. In vitro comparison with a classical anaesthesia machine.
    Br J Anaesth, 94(3): 306-17. [Abstract] [Full-text]
70. Latex D-dimer signal in in situ femoral vein thrombus in swine and effect of minidose exogenous tissue plasminogen activator bolus.
    Chest, 127(2): 622-9. [Abstract] [Full-text]
71. Association between hormone replacement therapy and subsequent stroke: a meta-analysis.
    BMJ, 330(7487): 342. [Abstract] [Full-text]
72. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
    Int J Epidemiol, 34(1): 121-30. [Abstract] [Full-text]
73. The role of mitoxantrone in the treatment of indolent lymphomas.
    Oncologist, 10(2): 150-9. [Abstract] [Full-text]
74. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Oncologist, 10(2): 138-49. [Abstract] [Full-text]
75. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
    Oncologist, 10(2): 132-7. [Abstract] [Full-text]
76. Acute pancreatitis during all-trans-retinoic acid treatment for acute promyelocytic leukemia in a patient without overt hypertriglyceridemia.
    Jpn J Clin Oncol, 35(2): 94-6. [Abstract] [Full-text]
77. Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
    Jpn J Clin Oncol, 35(2): 88-9. [Abstract] [Full-text]
78. Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
    Jpn J Clin Oncol, 35(2): 79-83. [Abstract] [Full-text]
79. Dietary and metabolic differences in pre- versus postmenopausal women taking or not taking hormone replacement therapy.
    Physiol Behav, 84(2): 303-12. [Abstract] [Full-text]
80. Formulation strategies for absorption windows.
    Drug Discov Today, 10(4): 249-57. [Abstract] [Full-text]
81. Primary angioplasty is cost-minimizing compared with pre-hospital thrombolysis for patients within 60 min of a percutaneous coronary intervention center: the Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) cost-efficacy sub-study.
    J Am Coll Cardiol, 45(4): 515-24. [Abstract] [Full-text]
82. Drug-eluting stents for diabetes mellitus: a rush to judgment?
    J Am Coll Cardiol, 45(4): 479-83. [Abstract] [Full-text]
83. Cytokine responses induced by Mycobacterium tuberculosis in patients with HIV-1 infection and tuberculosis.
    Int J Infect Dis, 9(2): 110-6. [Abstract] [Full-text]
84. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study.
    Int J Radiat Oncol Biol Phys, 61(3): 824-9. [Abstract] [Full-text]
85. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study.
    Int J Radiat Oncol Biol Phys, 61(3): 817-23. [Abstract] [Full-text]
86. Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome.
    Urology, 65(2): 395-9. [Abstract] [Full-text]
87. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer.
    Urology, 65(2): 295-9. [Abstract] [Full-text]
88. Clinicians and dyslexia--a computer-based assessment of one of the key cognitive skills involved in drug administration.
    Int J Nurs Stud, 42(3): 341-53. [Abstract] [Full-text]
89. Liver metastases from breast cancer: management of patients with significant liver dysfunction.
    Cancer Treat Rev, 31(1): 35-48. [Abstract] [Full-text]
90. Graduate nurses' communication with health professionals when managing patients' medications.
    J Clin Nurs, 14(3): 354-62. [Abstract] [Full-text]
91. Gender differences in the administration of prophylaxis to prevent deep venous thrombosis.
    Thromb Haemost, 93(2): 284-8. [Abstract] [Full-text]
92. FRET-FCS as a tool to evaluate the stability of oligonucleotide drugs after intracellular delivery.
    J Control Release, 103(1): 259-71. [Abstract] [Full-text]
93. Self-assembled nanoparticles containing hydrophobically modified glycol chitosan for gene delivery.
    J Control Release, 103(1): 235-43. [Abstract] [Full-text]
94. Polyethylenimine with acid-labile linkages as a biodegradable gene carrier.
    J Control Release, 103(1): 209-19. [Abstract] [Full-text]
95. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery.
    J Control Release, 103(1): 159-75. [Abstract] [Full-text]
96. Polymeric micellar pH-sensitive drug delivery system for doxorubicin.
    J Control Release, 103(1): 137-48. [Abstract] [Full-text]
97. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle-skin interaction.
    J Control Release, 103(1): 123-36. [Abstract] [Full-text]
98. Factorial design approach to evaluate interactions between electrically assisted enhancement and skin stripping for delivery of tacrine.
    J Control Release, 103(1): 113-21. [Abstract] [Full-text]
99. Drug-incorporating calcium carbonate nanoparticles for a new delivery system.
    J Control Release, 103(1): 93-8. [Abstract] [Full-text]
100. Physically bonded nanoparticle networks: a novel drug delivery system.
     J Control Release, 103(1): 21-30. [Abstract] [Full-text]
101. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel.
     J Control Release, 103(1): 7-19. [Abstract] [Full-text]
102. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era.
     J Hepatol, 42(3): 309-14. [Abstract] [Full-text]
103. Medication errors in anaesthesia and critical care.
     Anaesthesia, 60(3): 257-73. [Abstract] [Full-text]
104. Drug error in anaesthetic practice: a review of 896 reports from the Australian Incident Monitoring Study database.
     Anaesthesia, 60(3): 220-7. [Abstract] [Full-text]
105. Primary chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil in operable breast carcinoma.
     Cancer, 103(4): 657-63. [Abstract] [Full-text]
106. A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma.
     Cancer, 103(4): 772-9. [Abstract] [Full-text]
107. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma.
     Cancer, 103(4): 850-7. [Abstract] [Full-text]
108. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma.
     Cancer, 103(4): 672-9. [Abstract] [Full-text]
109. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
     Cancer, 103(4): 756-62. [Abstract] [Full-text]
110. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
     Cancer, 103(4): 802-9. [Abstract] [Full-text]
111. Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: results from a Los Angeles County case-control study.
     Int J Cancer, 114(4): 634-8. [Abstract] [Full-text]
112. Effects of surgical menopause and estrogen replacement therapy on serum paraoxonase activity and plasma malondialdehyde concentration.
     Gynecol Obstet Invest, 59(2): 108-12. [Abstract] [Full-text]
113. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
     JAMA, 293(7): 817-29. [Abstract] [Full-text]
114. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
     Lung Cancer, 47(3): 413-9. [Abstract] [Full-text]
115. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC).
     Lung Cancer, 47(3): 395-404. [Abstract] [Full-text]
116. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
     Lung Cancer, 47(3): 385-94. [Abstract] [Full-text]
117. A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated.
     Lung Cancer, 47(3): 373-80. [Abstract] [Full-text]
118. The influence of cyclic loading on gentamicin release from acrylic bone cements.
     J Biomech, 38(4): 953-7. [Abstract] [Full-text]
119. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.
     Eur Heart J, 26(5): 440-6. [Abstract] [Full-text]
120. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy.
     Cancer Gene Ther, 12(3): 257-67. [Abstract] [Full-text]
121. Efficacy of articaine and lidocaine in a primary intraligamentary injection administered with a computer-controlled local anesthetic delivery system.
     Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 99(3): 361-6. [Abstract] [Full-text]
122. Oral candidosis as a clinical marker of immune failure in patients with HIV/AIDS on HAART.
     AIDS Patient Care STDS, 19(2): 70-7. [Abstract] [Full-text]
123. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
     J Neurooncol, 71(1): 61-5. [Abstract] [Full-text]
124. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
     J Neurooncol, 71(1): 33-8. [Abstract] [Full-text]
125. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
     J Clin Oncol, 23(6): 1295-311. [Abstract] [Full-text]
126. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
     J Clin Oncol, 23(6): 1253-60. [Abstract] [Full-text]
127. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
     J Clin Oncol, 23(6): 1237-44. [Abstract] [Full-text]
128. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.
     J Clin Oncol, 23(6): 1228-36. [Abstract] [Full-text]
129. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
     J Clin Oncol, 23(6): 1185-91. [Abstract] [Full-text]
130. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study.
     J Clin Oncol, 23(6): 1144-51. [Abstract] [Full-text]
131. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
     J Clin Oncol, 23(6): 1125-35. [Abstract] [Full-text]
132. Inhibiting protein-protein interactions using designed molecules.
     Curr Opin Struct Biol, 15(1): 31-4. [Abstract] [Full-text]
133. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials.
     J Clin Oncol, 23(6): 1118-24. [Abstract] [Full-text]
134. Biochemical modulation of cytarabine triphosphate by clofarabine.
     Cancer Chemother Pharmacol, 55(4): 361-8. [Abstract] [Full-text]
135. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
     Cancer Chemother Pharmacol, 55(4): 354-60. [Abstract] [Full-text]
136. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
     Cancer Chemother Pharmacol, 55(4): 307-17. [Abstract] [Full-text]
137. Alzheimer's associated inflammation, potential drug targets and future therapies.
     J Neural Transm, 112(3): 429-53. [Abstract] [Full-text]
138. Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration.
     Br J Ophthalmol, 89(3): 312-5. [Abstract] [Full-text]
139. Cell-penetrating peptides: mechanism and kinetics of cargo delivery.
     Adv Drug Deliv Rev, 57(4): 529-45. [Abstract] [Full-text]
140. Application of pharmaceuticals to nitric oxide.
     Mol Aspects Med, 26(1): 97-138. [Abstract] [Full-text]
141. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating.
     Brain Res, 1035(2): 139-53. [Abstract] [Full-text]
142. Targeted contrast agents for magnetic resonance imaging and ultrasound.
     Curr Opin Biotechnol, 16(1): 89-92. [Abstract] [Full-text]
143. What do discharged patients know about their medication?
     Patient Educ Couns, 56(3): 276-82. [Abstract] [Full-text]
144. The Women's Health Initiative Memory Study: findings and implications for treatment.
     Lancet Neurol, 4(3): 190-4. [Abstract] [Full-text]
145. Effectiveness and safety of the thrombolytic therapy for acute pulmonary thromboembolism: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research.
     Int J Cardiol, 99(1): 83-9. [Abstract] [Full-text]
146. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature.
     Gynecol Oncol, 96(3): 865-9. [Abstract] [Full-text]
147. Ovarian luteinized thecoma with sclerosing peritonitis in an adult woman treated with leuprolide and toremifene in complete remission at 5 years.
     Gynecol Oncol, 96(3): 846-9. [Abstract] [Full-text]
148. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.
     Gynecol Oncol, 96(3): 805-9. [Abstract] [Full-text]
149. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
     Gynecol Oncol, 96(3): 630-4. [Abstract] [Full-text]
150. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
     Gynecol Oncol, 96(3): 610-5. [Abstract] [Full-text]
151. Liposomal superoxide dismutases and their use in the treatment of experimental arthritis.
     Methods Enzymol, 391: 395-413. [Abstract] [Full-text]
152. Liposomal vasoactive intestinal peptide.
     Methods Enzymol, 391: 377-95. [Abstract] [Full-text]
153. Delivery of antiviral agents in liposomes.
     Methods Enzymol, 391: 351-73. [Abstract] [Full-text]
154. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
     Methods Enzymol, 391: 330-51. [Abstract] [Full-text]
155. Drug delivery by lipid cochleates.
     Methods Enzymol, 391: 314-29. [Abstract] [Full-text]
156. Liposomal polyene antibiotics.
     Methods Enzymol, 391: 304-13. [Abstract] [Full-text]
157. Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections.
     Methods Enzymol, 391: 291-304. [Abstract] [Full-text]
158. Liposome-encapsulated antibiotics.
     Methods Enzymol, 391: 261-91. [Abstract] [Full-text]
159. Long-circulating sterically stabilized liposomes in the treatment of infections.
     Methods Enzymol, 391: 228-60. [Abstract] [Full-text]
160. Use of liposomes to deliver bactericides to bacterial biofilms.
     Methods Enzymol, 391: 211-28. [Abstract] [Full-text]
161. Methodology and experimental design for the study of liposome-dependent drugs.
     Methods Enzymol, 391: 186-99. [Abstract] [Full-text]
162. Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice.
     Methods Enzymol, 391: 176-85. [Abstract] [Full-text]
163. Liposomalized oligopeptides in cancer therapy.
     Methods Enzymol, 391: 163-76. [Abstract] [Full-text]
164. Cisplatin nanocapsules.
     Methods Enzymol, 391: 118-25. [Abstract] [Full-text]
165. Preparation and characterization of taxane-containing liposomes.
     Methods Enzymol, 391: 97-117. [Abstract] [Full-text]
166. The liposomal formulation of doxorubicin.
     Methods Enzymol, 391: 71-97. [Abstract] [Full-text]
167. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
     Methods Enzymol, 391: 58-70. [Abstract] [Full-text]
168. Preparation, characterization, and biological analysis of liposomal formulations of vincristine.
     Methods Enzymol, 391: 40-57. [Abstract] [Full-text]
169. Entrapment of small molecules and nucleic acid-based drugs in liposomes.
     Methods Enzymol, 391: 7-40. [Abstract] [Full-text]
170. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
     Am J Cardiol, 95(5): 611-4. [Abstract] [Full-text]
171. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
     Am J Cardiol, 95(5): 586-91. [Abstract] [Full-text]
172. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial.
     Atherosclerosis, 179(1): 193-200. [Abstract] [Full-text]
173. STRAP is a strong predictive marker of adjuvant chemotherapy benefit in colorectal cancer.
     Neoplasia, 6(6): 813-20. [Abstract] [Full-text]
174. In-vitro evaluation of khaya and albizia gums as compression coatings for drug targeting to the colon.
     J Pharm Pharmacol, 57(2): 163-8. [Abstract] [Full-text]
175. Do rural consumers expect a prescription from their GP visit? Investigation of patients' expectations for a prescription and doctors' prescribing decisions in rural Australia.
     Aust J Rural Health, 13(1): 43-50. [Abstract] [Full-text]
176. Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.
     Ann Oncol, 16(3): 466-72. [Abstract] [Full-text]
177. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
     Ann Oncol, 16(3): 425-9. [Abstract] [Full-text]
178. Chemotherapy options and new advances in malignant pleural mesothelioma.
     Ann Oncol, 16(3): 345-51. [Abstract] [Full-text]
179. Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy.
     Ann Oncol, 16(3): 372-82. [Abstract] [Full-text]
180. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
     Ann Oncol, 16(3): 419-24. [Abstract] [Full-text]
181. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
     Ann Oncol, 16(3): 411-8. [Abstract] [Full-text]
182. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer.
     Ann Oncol, 16(3): 430-6. [Abstract] [Full-text]
183. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital.
     Ann Oncol, 16(3): 437-44. [Abstract] [Full-text]
184. Does cisplatin (CDDP) function as a modulator of 5-fluorouracil (5-FU) antitumor action? A study based on a clinical trial.
     Cancer Chemother Pharmacol, 55(4): 387-92. [Abstract] [Full-text]
185. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment.
     Pediatr Blood Cancer, 44(4): 378-85. [Abstract] [Full-text]
186. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.
     J Biol Chem, 280(8): 6327-36. [Abstract] [Full-text]
187. The mystical effects of dermatological vehicles.
     Dermatology, 210(2): 157-68. [Abstract] [Full-text]
188. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project.
     Arch Surg, 140(2): 174-82. [Abstract] [Full-text]
189. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis.
     Arch Otolaryngol Head Neck Surg, 131(2): 99-105. [Abstract] [Full-text]
190. Monitoring PDT-induced damage using spectrally resolved reflectance imaging of tissue oxygenation.
     Cancer Lett, 219(2): 169-75. [Abstract] [Full-text]
191. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association.
     Circulation, 111(7): 940-53. [Abstract] [Full-text]
192. The importance of chemotherapy dose intensity in lung cancer.
     Semin Oncol, 31(6): 25-31. [Abstract] [Full-text]
193. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.
     Semin Oncol, 31(6): 19-24. [Abstract] [Full-text]
194. Perspectives in the treatment of colorectal cancer.
     Semin Oncol, 31(6): 14-8. [Abstract] [Full-text]
195. New treatment strategies for aggressive lymphoma.
     Semin Oncol, 31(6): 10-3. [Abstract] [Full-text]
196. Cytoprotection in acute myelogenous leukemia (AML) therapy.
     Semin Oncol, 31(6): 67-73. [Abstract] [Full-text]
197. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
     Semin Oncol, 31(6): 59-61. [Abstract] [Full-text]
198. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
     Semin Oncol, 31(6): 47-51. [Abstract] [Full-text]
199. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
     Semin Oncol, 31(6): 42-6. [Abstract] [Full-text]
200. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
     Semin Oncol, 31(6): 13-9. [Abstract] [Full-text]
201. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
     Semin Oncol, 31(6): 2-7. [Abstract] [Full-text]
202. Adjuvant therapy of colon cancer.
     Semin Oncol, 32(1): 95-102. [Abstract] [Full-text]
203. Stimuli responsive polymers for biomedical applications.
     Chem Soc Rev, 34(3): 276-85. [Abstract] [Full-text]
204. Non-covalent side-chain polymers: design principles, functionalization strategies, and perspectives.
     Chem Soc Rev, 34(3): 193-207. [Abstract] [Full-text]
205. Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy--a longitudinal study.
     Br J Cancer, 92(4): 673-80. [Abstract] [Full-text]
206. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group.
     Br J Cancer, 92(4): 639-44. [Abstract] [Full-text]
207. Chemotherapy-induced scleroderma: a pleiomorphic syndrome.
     Clin Exp Dermatol, 30(2): 141-5. [Abstract] [Full-text]
208. Targeted therapies in breast cancer.
     Breast J, 11: S30-5. [Abstract] [Full-text]
209. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
     Br J Haematol, 128(5): 631-5. [Abstract] [Full-text]
210. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
     Br J Cancer, 92(4): 681-9. [Abstract] [Full-text]
211. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
     Br J Cancer, 92(4): 722-8. [Abstract] [Full-text]
212. Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial.
     Br J Cancer, 92(4): 655-61. [Abstract] [Full-text]
213. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
     Br J Cancer, 92(4): 645-50. [Abstract] [Full-text]
214. An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.
     Cancer, 103(5): 978-84. [Abstract] [Full-text]
215. Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines.
     Br J Cancer, 92(4): 634-8. [Abstract] [Full-text]
216. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
     Cancer, 103(5): 970-7. [Abstract] [Full-text]
217. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine.
     Cancer, 103(5): 994-9. [Abstract] [Full-text]
218. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
     Bone Marrow Transplant, 35(5): 467-71. [Abstract] [Full-text]
219. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
     Bone Marrow Transplant, 35(5): 449-54. [Abstract] [Full-text]
220. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
     Cancer, 103(5): 1008-17. [Abstract] [Full-text]
221. The benefit of chemotherapy in a patient with multiple brain metastases and meningitis carcinomatosa from ovarian cancer.
     Int J Clin Oncol, 10(1): 69-71. [Abstract] [Full-text]
222. Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only.
     Int J Clin Oncol, 10(1): 63-8. [Abstract] [Full-text]
223. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen.
     Int J Clin Oncol, 10(1): 40-4. [Abstract] [Full-text]
224. Analysis of HIV- type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART).
     Rev Inst Med Trop Sao Paulo, 47(1): 1-5. [Abstract] [Full-text]
225. Bactericidal effects of toluidine blue-mediated photodynamic action on Vibrio vulnificus.
     Antimicrob Agents Chemother, 49(3): 895-902. [Abstract] [Full-text]
226. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.
     Neurology, 64(4): 719-20. [Abstract] [Full-text]
227. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke.
     Neurology, 64(4): 654-9. [Abstract] [Full-text]
228. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?
     JAMA, 293(8): 979-86. [Abstract] [Full-text]
229. Effects of estrogen with and without progestin on urinary incontinence.
     JAMA, 293(8): 935-48. [Abstract] [Full-text]
230. Preoperative intravenous fluid therapy decreases postoperative nausea and pain in high risk patients.
     Anesth Analg, 100(3): 675-82, table of contents. [Abstract] [Full-text]
231. Intraoperative blood salvage: fluid replacement calculations.
     Anesth Analg, 100(3): 645-9, table of contents. [Abstract] [Full-text]
232. Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study.
     Br J Dermatol, 152(2): 279-83. [Abstract] [Full-text]
233. MR imaging of biodegradable polymeric microparticles: a potential method of monitoring local drug delivery.
     Magn Reson Med, 53(3): 614-20. [Abstract] [Full-text]
234. Adverse drug reaction and medication error reporting by pharmacy students.
     Ann Pharmacother, 39(3): 452-9. [Abstract] [Full-text]
235. Potential drug-disease interactions in frail, hospitalized elderly veterans.
     Ann Pharmacother, 39(3): 412-7. [Abstract] [Full-text]
236. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome.
     Leukemia, 19(3): 396-401. [Abstract] [Full-text]
237. Adverse outcomes associated with inappropriate drug use in nursing homes.
     Ann Pharmacother, 39(3): 405-11. [Abstract] [Full-text]
238. Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy.
     J Virol, 79(6): 3653-63. [Abstract] [Full-text]
239. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
     Clin Endocrinol (Oxf), 62(3): 349-53. [Abstract] [Full-text]
240. Sclerosant therapy as first-line treatment for solitary liver cysts.
     Dig Surg, 21(5): 452-4. [Abstract] [Full-text]
241. A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
     J Neurooncol, 71(3): 301-5. [Abstract] [Full-text]
242. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.
     J Neurooncol, 71(3): 295-9. [Abstract] [Full-text]
243. Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study.
     J Neurooncol, 71(3): 271-6. [Abstract] [Full-text]
244. Double-platinum chemotherapy combined with etoposide in metastatic brain tumor from small cell lung carcinoma.
     J Neurooncol, 71(3): 259-65. [Abstract] [Full-text]
245. Limited benefits of ambulance telemetry in delivering early thrombolysis: a randomised controlled trial.
     Emerg Med J, 22(3): 209-15. [Abstract] [Full-text]
246. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
     J Clin Oncol, 23(7): 1439-46. [Abstract] [Full-text]
247. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
     J Clin Oncol, 23(7): 1401-8. [Abstract] [Full-text]
248. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
     Cancer Res, 65(4): 1459-70. [Abstract] [Full-text]
249. The role of hormone replacement therapy in endometrial polyp formation.
     Maturitas, 50(3): 231-6. [Abstract] [Full-text]
250. The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women.
     Maturitas, 50(3): 189-95. [Abstract] [Full-text]
251. Fast-dissolving mucoadhesive microparticulate delivery system containing piroxicam.
     Eur J Pharm Sci, 24(4): 355-61. [Abstract] [Full-text]
252. Objective analysis of retinal damage in HIV-positive patients in the HAART era using OCT.
     Am J Ophthalmol, 139(2): 295-301. [Abstract] [Full-text]
253. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women.
     Thromb Res, 115(5): 359-66. [Abstract] [Full-text]
254. An evaluation of children's metered-dose inhaler technique for asthma medications.
     Nurs Clin North Am, 40(1): 167-82. [Abstract] [Full-text]
255. Antibiotic resistance.
     Nurs Clin North Am, 40(1): 63-75. [Abstract] [Full-text]
256. Strategies for acquiring affordable medications for seniors.
     Nurs Clin North Am, 40(1): 51-62, vi. [Abstract] [Full-text]
257. Use of prescription drugs: rising or declining?
     Nurs Clin North Am, 40(1): 33-49. [Abstract] [Full-text]
258. Reduction of adverse drug events and medication errors in a community hospital setting.
     Nurs Clin North Am, 40(1): 25-32. [Abstract] [Full-text]
259. The risk of disciplinary action by state medical boards against physicians prescribing opioids.
     J Pain Symptom Manage, 29(2): 206-12. [Abstract] [Full-text]
260. Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery.
     Int J Urol, 12(2): 208-10. [Abstract] [Full-text]
261. Favorable outcome of Ewing sarcoma family tumors to multiagent intensive preoperative chemotherapy: a single institution experience.
     J Surg Oncol, 89(4): 239-43. [Abstract] [Full-text]
262. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
     J Surg Oncol, 89(4): 227-36; discussion 237-8. [Abstract] [Full-text]
263. Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus.
     J Surg Oncol, 89(4): 244-50; discussion 250. [Abstract] [Full-text]
264. Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer.
     J Surg Oncol, 89(4): 256-63; discussion 263-4. [Abstract] [Full-text]
265. Cellular evaluation of oral chemotherapy carriers.
     J Biomed Mater Res A, 72(4): 381-8. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.